Skip to main content
Journal cover image

The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.

Publication ,  Journal Article
Feng, J; Hao, S; Pan, C; Wang, Y; Wu, Z; Zhang, J; Yan, H; Zhang, L; Wan, H
Published in: Hum Pathol
November 2015

Brainstem and thalamic gliomas are rare, and they are poorly understood in adults. Genetic aberrations that occur in these tumors are still unknown. In this study, we investigated whether thalamic gliomas have different genetic aberrations and clinical outcomes compared with brainstem gliomas in adults. Forty-three glioma samples were selected, including 28 brainstem and 15 thalamic gliomas. The frequency of the K27M mutation in adult midline gliomas was 58.1%. High-grade gliomas in the thalamus were statistically significantly more numerous than brainstem gliomas. Patients with K27M mutant brainstem gliomas had a significantly shorter overall survival than patients with wild-type tumors (P = .020) by Cox regression after adjustment for other independent risk factors. However, there was no statistical tendency toward a poorer overall survival in thalamic gliomas containing the K27M mutation compared with wild-type tumors. The presence of the K27M mutation significantly corresponded with mutations in TP53 in thalamic gliomas. Interestingly, the K27M mutation was mutually exclusive with mutations in IDH1, which was detected only in brainstem gliomas. The microarray data identified 86 differentially expressed genes between brainstem and thalamic gliomas with the K27M mutation. The cyclin-dependent kinase 6 (CDK6) gene, which plays an important role in cancer pathways, was found to be differentially expressed between brainstem and thalamic gliomas with K27M mutations. Although the K27M mutation was frequently observed in adult brainstem and thalamic gliomas, this mutation tended to be associated with a poorer prognosis in brainstem gliomas but not in thalamic gliomas. Brainstem gliomas may present different genetic aberrations from thalamic gliomas. These differences may provide guidance for therapeutic decisions for the treatment of adult brainstem and thalamic gliomas, which may have different molecular targets.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hum Pathol

DOI

EISSN

1532-8392

Publication Date

November 2015

Volume

46

Issue

11

Start / End Page

1626 / 1632

Location

United States

Related Subject Headings

  • Young Adult
  • Thalamus
  • Survival Rate
  • Prognosis
  • Pathology
  • Mutation
  • Middle Aged
  • Male
  • Humans
  • Histones
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feng, J., Hao, S., Pan, C., Wang, Y., Wu, Z., Zhang, J., … Wan, H. (2015). The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol, 46(11), 1626–1632. https://doi.org/10.1016/j.humpath.2015.07.002
Feng, Jie, Shuyu Hao, Changcun Pan, Yu Wang, Zhen Wu, Junting Zhang, Hai Yan, Liwei Zhang, and Hong Wan. “The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.Hum Pathol 46, no. 11 (November 2015): 1626–32. https://doi.org/10.1016/j.humpath.2015.07.002.
Feng J, Hao S, Pan C, Wang Y, Wu Z, Zhang J, et al. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol. 2015 Nov;46(11):1626–32.
Feng, Jie, et al. “The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.Hum Pathol, vol. 46, no. 11, Nov. 2015, pp. 1626–32. Pubmed, doi:10.1016/j.humpath.2015.07.002.
Feng J, Hao S, Pan C, Wang Y, Wu Z, Zhang J, Yan H, Zhang L, Wan H. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol. 2015 Nov;46(11):1626–1632.
Journal cover image

Published In

Hum Pathol

DOI

EISSN

1532-8392

Publication Date

November 2015

Volume

46

Issue

11

Start / End Page

1626 / 1632

Location

United States

Related Subject Headings

  • Young Adult
  • Thalamus
  • Survival Rate
  • Prognosis
  • Pathology
  • Mutation
  • Middle Aged
  • Male
  • Humans
  • Histones